OncoSolid™ Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Services

Are you encountering translational challenges due to the poor clinical concordance of traditional 2D models and the difficulty in predicting off-target toxicity for solid tumor CAR-T therapies? Creative Biolabs' OncoSolid™ Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Services is designed to bridge this gap. We provide high-fidelity, patient-derived 3D co-culture models that fully recapitulate the complex tumor microenvironment (TME), enabling robust and predictive efficacy testing. Our model empowers you to accelerate lead candidate development and streamline patient stratification with greater confidence.

Introduction

The clinical application of CAR-T therapy is currently constrained by three major factors: the high heterogeneity of solid tumors, the TME, and the lack of preclinical models that accurately mimic the complexity of human physiology. To address these challenges, tumor organoid models, particularly patient-derived organoids (PDOs), have been introduced into the preclinical research framework for CAR-T therapy. These organoid models closely retain the histopathological architecture, genomic features, and specific marker expression profiles of the original tumors, thereby providing a more physiologically relevant evaluation platform that effectively overcomes the limitations of traditional cell lines and patient-derived xenograft (PDX) models in preserving TME integrity.

Fig.1 Exploring the potential applications of modified tumor organoids in co-culture models with CAR-T cells.^1,3

OncoSolid™ Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Services at Creative Biolabs

Creative Biolabs' OncoSolid™ Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Services delivers the critical functional data you need to advance your lead candidates with confidence. We go beyond simplistic cytotoxicity assays to provide a physiologically relevant in vitro system that accurately recapitulates immune cell infiltration, persistence, and functional exhaustion within a complex 3D tumor microenvironment. The result is highly predictive data that directly informs decisive go/no-go decisions for your clinical development pathway.

What we can offer

Our integrated service platform provides a comprehensive suite of solutions for evaluating CAR-T cell efficacy using highly validated cancer organoid models, combining diverse organoid types, advanced culture systems, and multi-dimensional analytical methods to accelerate therapeutic development with physiological relevance and high predictive power.

• Organoid Types

We offer distinct organoids, enabling researchers to address either clinically representative heterogeneity or specific mechanistic questions.

• Available Culture Methods

To balance physiological fidelity with practical scalability, our platform supports multiple culture systems. Each system is optimized to maintain TME complexity and support long-term co-culture with immune cells.

Fig.3 Distinct culture techniques of organoids and immune cells.^2,3

• Multiple Types of Cancer Organoids

Our extensively bio-banked organoid models cover a broad spectrum of cancer types, each rigorously validated at histological and genomic levels. This diversity ensures alignment with specific research needs, whether for population-wide therapeutic screening or rare mutation-specific investigations.

• Cancer Organoid Models-based CAR-T Efficacy Test Services

We deliver end-to-end functional analyses through quantitative high-content imaging, allowing real-time monitoring of CAR-T cell infiltration, tumor killing dynamics, and functional immune responses, providing actionable data for efficacy and safety assessment.

Our Service Process

We offer an integrated and end-to-end service platform for evaluating CAR-T efficacy using patient-derived cancer organoids.

Key Advantages

• Broad Clinical Relevance: Our extensive and well-characterized biobank of tumor organoids captures population diversity and tumor heterogeneity, ensuring your research findings possess strong potential for clinical translation.
• High-Throughput Parallel Screening: Our advanced high-throughput platform enables simultaneous testing of multiple CAR-T cell and organoid model combinations, significantly accelerating screening efficiency and facilitating the rapid identification of optimal candidate therapies.
• Reliable Safety Assessment: We provide well-sourced normal organoids specifically for evaluating potential off-target toxicity of CAR-T cells, delivering critical safety data to support the transition of your therapy into preclinical development.

FAQ

Why Choose Us?

Our OncoSolid™ platform delivers exceptional clinical predictive value by integrating biologically relevant TME with advanced functional assays. We offer unmatched clinical concordance in solid tumor response modeling, proactive toxicity assessment using patient-matched normal organoids and neurotoxicity models, and expert support for combination therapy screening.

Customer Reviews

"Using Creative Biolabs' OncoSolid™ in our research has significantly improved our ability to model intrinsic resistance. The presence of viable CAFs and the dense ECM layer is crucial; we finally see CAR-T products failing in vitro for the same reasons they fail in the clinic, unlike our old 2D assays."— Dr. Sna, Research Director.

"The comparative analysis against healthy normal organoids provided by Creative Biolabs was essential. We specifically looked at liver and kidney organoid models, which allowed us to identify a systemic toxicity liability in our second-generation CAR before moving to in vivo studies, saving us substantial time and resources"— Jonathan, Translational Lead.

How to contact us?

To address the unique challenges in your CAR-T program, we invite you to connect with our specialists. Discover how to leverage the adaptable OncoSolid™ platform to de-risk and accelerate your path to the clinic.

Partner with Our Scientific Team – Receive a Precise Quote for Your Needs.

References

1. Ning, Rong-Xuan et al. "Application status and optimization suggestions of tumor organoids and CAR-T cell co-culture models." Cancer cell international vol. 24,1 98. https://doi.org/10.1186/s12935-024-03272-x.
2. Gunti, Sreenivasulu et al. "Organoid and Spheroid Tumor Models: Techniques and Applications." Cancers vol. 13,4 874. https://doi.org/10.3390/cancers13040874.
3. Distributed under Open Access License CC BY 4.0, without modification.